tralokinumab-话题@MedSci

#tralokinumab#

7篇内容 | 1338人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2089154, encodeId=cd282089154d2, content=全球领先的皮肤病医疗机构<a href='/topic/show?id=40d0104e7513' target=_blank style='color:#2F92EE;'>#LEO Pharma#</a> A/S今天宣布，<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>(EMA)人用医药产品委员会(CHMP)已采纳积极意见，建议扩大Adtralza® (<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>)在欧盟的批准使用范围，将12至17岁的中重度<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>的青少年纳入系统治疗的对象。青少年患者的推荐初始剂量为600 mg，然后每隔一周使用300 mg，与成年患者的剂量相同。, objectTitle=LEO Pharma获得人用医药产品委员会关于Adtralza® (tralokinumab)治疗青少年中度至重度特应性皮炎的积极意见, objectType=article, longId=740013, objectId=dcbce4001380, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220919/1663570737482_5444305.png, objectUrl=/article/show_article.do?id=dcbce4001380, replyNumber=0, likeNumber=108, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcbce4001380, moduleTitle=LEO Pharma获得人用医药产品委员会关于Adtralza® (tralokinumab)治疗青少年中度至重度特应性皮炎的积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcbce4001380)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1542761, encodeId=13991542e61d1, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, objectType=article, longId=293187, objectId=acae29318e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acae29318e52, replyNumber=0, likeNumber=80, createdTime=2022-01-01, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acae29318e52, moduleTitle=LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acae29318e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1542760, encodeId=c2e71542e60c4, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=FDA接受Tralokinumab治疗中重度特应性皮炎的BLA, objectType=article, longId=197354, objectId=32da19e35447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32da19e35447, replyNumber=0, likeNumber=71, createdTime=2020-07-12, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32da19e35447, moduleTitle=FDA接受Tralokinumab治疗中重度特应性皮炎的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32da19e35447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1542759, encodeId=af381542e59d5, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, objectType=article, longId=195833, objectId=7404195833c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7404195833c3, replyNumber=0, likeNumber=97, createdTime=2020-06-15, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7404195833c3, moduleTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7404195833c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1542758, encodeId=bdf81542e5899, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, objectType=article, longId=138764, objectId=dc65138e6490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc65138e6490, replyNumber=0, likeNumber=64, createdTime=2018-05-23, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc65138e6490, moduleTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc65138e6490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1542757, encodeId=1acc1542e570c, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=Gut：Tralokinumab能有效缓解中重度溃疡性结肠炎, objectType=article, longId=41762, objectId=66ad41e62c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66ad41e62c5, replyNumber=0, likeNumber=67, createdTime=2014-10-29, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66ad41e62c5, moduleTitle=Gut：Tralokinumab能有效缓解中重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66ad41e62c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1542756, encodeId=28301542e564d, content=<a href='/topic/show?id=f1ab1e73777' target=_blank style='color:#2F92EE;'>#tralokinumab#</a>, objectTitle=阿斯利康启动哮喘生物药tralokinumab III期项目, objectType=article, longId=39219, objectId=261b3921955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=261b3921955, replyNumber=0, likeNumber=68, createdTime=2014-08-20, rootId=0, userName=丁鹏鹏, userId=1b1313466530, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=261b3921955, moduleTitle=阿斯利康启动哮喘生物药tralokinumab III期项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=261b3921955)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

tralokinumab

2020-05-29

小小医者 (审核中...)

前往app查看评论内容

全文收起全球领先的皮肤病医疗机构#LEO Pharma# A/S今天宣布，#欧洲药品管理局#(EMA)人用医药产品委员会(CHMP)已采纳积极意见，建议扩大Adtralza® (#tralokinumab#)在欧盟的批准使用范围，将12至17岁的中重度#特应性皮炎#的青少年纳入系统治疗的对象。青少年患者的推荐初始剂量为600 mg，然后每隔一周使用300 mg，与成年患者的剂量相同。

LEO Pharma获得人用医药产品委员会关于Adtralza® (tralokinumab)治疗青少年中度至重度特应性皮炎的积极意见

2022-09-20

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

LEO Pharma宣布FDA核准Adbry™ (tralokinumab)作为特异性靶向作用于中度至重度特应性皮炎成人IL-13的治疗药物

2022-01-01

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

FDA接受Tralokinumab治疗中重度特应性皮炎的BLA

2020-07-12

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎

2020-06-15

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估

2018-05-23

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

Gut：Tralokinumab能有效缓解中重度溃疡性结肠炎

2014-10-29

丁鹏鹏 (审核中...)

前往app查看评论内容

#tralokinumab#

阿斯利康启动哮喘生物药tralokinumab III期项目

2014-08-20

科室
- - 订阅+
  - 更多科室
工具
服务